FP
MRVI icon

Foundry Partners’s Maravai LifeSciences MRVI Stock Holding History

Foundry Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,677
Closed -$349K – 325
2022
Q3 		$349K Buy
13,677
+2,530
+23% +$63.5K 0.02% 261
2022
Q2 		$317K Sell
11,147
-1,502
-12% -$47.6K 0.02% 261
2022
Q1 		$446K Sell
12,649
-3,589
-22% -$120K 0.02% 260
2021
Q4 		$680K Buy
16,238
+2,897
+22% +$117K 0.02% 260
2021
Q3 		$655K Buy
+13,341
New +$651K 0.02% 276

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Foundry Partners's MRVI Position: Q4 2022 in Review

Foundry Partners sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 13,677 shares — an estimated $349K sold.

Foundry Partners first reported a position in MRVI in Q3 2021 and held it in 5 quarters. The position peaked at $680K in Q4 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

  • Foundry Partners reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
  • Foundry Partners sold 13,677 Maravai LifeSciences shares in Q4 2022, an estimated $349K.
  • Foundry Partners first reported a position in Maravai LifeSciences in Q3 2021 and held it in 5 quarters.
  • Foundry Partners's Maravai LifeSciences position peaked at $680K in Q4 2021.
  • 212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Foundry Partners's 13F filing for Q4 2022, filed 30 Jan 2023.